(A) Cytochrome P450 2D6 (CYP2D6) pharmacogenetics determined using the ratio of debrisoquine to its metabolite, 4-hydroxydebrisoquine, in 1,011 Swedish subjects. This population sample included a ...
This ongoing study uses minimal residual disease analysis at two follow-up points, to facilitate risk-adapted treatment stratification in ALL patients aged 1–18 years. In the current analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback